[1] Folkman J. Tumor angiogenesis:therapeutic implications[J]. N Engl J Med,1971,285(21):1182-1186.
[2] Bergers G,Benjamin LE.Tumorigenesis and the angiogenic switch[J]. Nat Rev Cancer,2003,3(6):401-410.
[3] Brem S,Brem H,Folkman J,et al. Prolonged tumor dormancy by prevention of neovascularization in the vitreous[J]. Cancer Res,1976,36(8):2807-2812.
[4] Fong TA,Shawver LK,Sun L,et al. Su5416 is a potent and selective inhibitor of the vascular tyrosine kinase catalysis,tumor vascularization,and growth endothelial growth factor receptor (Flk-1/KDR) that inhibits of multiple tumor types[J]. Cancer Res,1999,59(1):99-106.
[5] 吕金玲. 苹果酸舒尼替尼(sunitinib malate)[J]. 中国药物化学杂志,2007,17(3):194-194.
[6] Belleri M,Ribatti D,Nicoli S,et al. Antiangiogenic and vascular-targeting activity of the microtubule-destabilizing trans-resveratrol derivative 3,5,4'-trimethoxystilbene[J]. Mol Pharmacol,2005,67(5):1451-1459.
[7] Gieni RS,Li Y,Hayglass KT. Comparison of [3H] thymidine incorporation with MTT- and MTS-based bioassays for humanand murine IL-2 and IL-4 analysis.tetrazolium assays provide markedly enhanced sensitivity[J]. J Immunol Methods,1995,187(1):85-93.
[8] 张 帆,王晓欢,马俊杰.4,6-双苯基-2-氨基-3-氰基吡啶类化合物的合成及其抗肿瘤活性研究[J]. 中国药物化学杂志,2011,21(5):352-357.
[9] Hamel E. Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin[J]. Cell Biochem Biophys,2003,38(1):1-22.